Managing Partner, Harris Kaplan, published in Forbes
Oct 2021
Harris Kaplan, Red Team Associates’ Managing Partner, just published an article in Forbes, Biotech Investing: Is Hope Fueling Hype?. Hope is a major reason why people invest in biotech companies. Biotech investing offers the opportunity of financially doing well while also doing good. But hope can become hype and it is hard for average investors to sift signal from noise. Here, Harris provides one approach investors can use to determine whether the hope and hype surrounding sizzling science can actually result in successful products.
Managing Partner, Harris Kaplan, published in Forbes
Mar 2021
Harris Kaplan, Red Team Associates’ Managing Partner, just published an article in Forbes, All That Glitters Isn't Gold: Questions To Ask Yourself Before Investing In Biotech. 2020 was a golden year for biotech investing, but does that translate into commercially successful products? Take a read for 3 questions you may want to consider before investing in biotech.
Virtual Health Care: Where Does This Leave Pharma Marketing?
Sep 2020
Managing partner, Harris Kaplan, participated in Pharma intelligence‘s 24-hour web event on COVID-19: Lessons Learned and a Path Forward back in July. Session moderator, Melanie Senior, has written a piece for Informa, Virtual Health Care: Where Does This Leave Pharma Marketing?, recounting many of the learnings from Harris’ session, How COVID-19 is Changing Healthcare Delivery.
Virtual Health Care: Where Does This Leave Pharma Marketing?
Jan 2019
Harris Kaplan, Managing Partner, has partnered with Fred Dotzler to write the cover story for InVivo January 2019. The article delves into what payers are doing in today’s world to try to control the cost of new life science products, and what steps they plan on taking to better control rising costs in the future.
Payer Power: What Are The Future Implications For Life Science Companies Developing New Products?
Managing Partner, Harris Kaplan, published in Forbes
Jul 2021
Harris Kaplan, Red Team Associates’ Managing Partner, just published an article in Forbes, The Importance Of Being An Optimistic Realist In Biotech Investing. Investors in biotech need to be optimistic realists. They need to consider and balance two views of every investment: the optimism of the new and exciting science with the realism that there’s a low probability the science will translate into successful products. Take a read for Harris' take on how to be a successful optimistic realist.
Managing Partner, Harris Kaplan, published in PharmExec
Nov 2020
Harris Kaplan, Red Team Associates’ Managing Partner, just published an article in PharmExec (titled Marketers: Physicians are People First) that looks at how the COVID pandemic has impacted physicians through the lens of physicians. Using Maslow’s hierarchy of needs as a framework for understanding what physicians are thinking and doing, the article describes how physicians’ priorities have changed and how pharma and biotech companies need to adapt their communications and programs if they want to get physicians’ attention during this difficult time.
Join us for Informa’s 24-Hour Web Event – COVID-19: Lesson Learned and a Path Forward
Jul 2020
We are pleased to announce that Harris Kaplan, Managing Partner, will be participating in a new 24-hour web event, hosted by Informa, a leading international events, intelligence and scholarly research group. He will be joined by other experts and key opinion leaders from across Biopharma, MedTech, and healthcare as we discuss the impacts of the COVID-19 pandemic and what has been learned so far.
For 24 hours, subject-matter experts will give you an exclusive view into how our industries have responded and adapted to COVID-19 across a series of webinars and virtual events.
Managing Partner, Harris Kaplan, published in PM360
Apr 2021
Harris Kaplan, Red Team Associates’ Managing Partner, just published an article on PM360, Into the Mind of the Payer. Harris has interviewed countless payers over the years, covering hundreds of millions of lives. When a new product is approved by the FDA, medical directors at payers have to decide how their plan is going to cover it, and they've got an evaluation process and product impact assessment you need to understand to be successful.
Join us for Informa’s Newest Webinar – Transforming Cancer Treatment with Early Detection Diagnostics: Opportunities and Obstacles
Oct 2020
We are pleased to announce that on October 22, RTA’s Managing Partner, Harris Kaplan, will be joined by experts in the oncology field, where together they’ll discuss how patients can have better outcomes and cost savings through the use of early stage cancer detection tools and technology.
Register here for this exciting free webinar hosted by Pharma intelligence | informa
Lori Thompson, RTA Managing Director, guests blogs on MedTech Strategist
Jun 2020
Lori Thompson, Red Team Associates Managing Director, is guest blogging this week over at MedTech Strategist. The topic: thinking about your regulatory strategy as a key part of your overall commercial strategy. See Lori's thoughts on taking the 510(k) vs PMA pathway.